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The deletion of the protein phosphatase-1 (PP1) regulator known as Nuclear Inhibitor of PP1
(NIPP1) is embryonic lethal during gastrulation, hinting at a key role of PP1-NIPP1 in lineage spec-
iﬁcation. Consistent with this notion we show here that a mild, stable overexpression of NIPP1 in
HeLa cells caused a massive induction of genes of the mesenchymal lineage, in particular
smooth/cardiac-muscle and matrix markers. This reprogramming was associated with the forma-
tion of actin-based stress ﬁbers and retracting ﬁlopodia, and a reduced proliferation potential.
The NIPP1-induced mesenchymal transition required functional substrate and PP1-binding
domains, suggesting that it involves the selective dephosphorylation of substrates of PP1-NIPP1.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction [6,7]. The recruitment of substrates by the PP1-NIPP1 holoenzymePP1 is one of sevenmembers of the PPP-type superfamily of pro-
tein Ser/Thr phosphatases, which together catalyze the largemajor-
ity of all protein dephosphorylation events in eukaryotes [1,2]. It
forms oligomeric complexes with dozens of PP1-interacting pro-
teins (PIPs) that determine the subcellular localization, substrate
selectivity and speciﬁc activity of the phosphatase. One of themajor
nuclear PIPs in multicellular eukaryotes is NIPP1, for nuclear
inhibitor of PP1. NIPP1 forms a heterodimer with a considerable
fraction of the nuclear pool of PP1 [3]. It contains an essential cen-
tral PP1-anchoring domain [4,5] and a C-terminal PP1-inhibitory
domain [6]. Mutation of the central PP1-anchoring motif
200RVTF203? 200RATA203 (residue numbers in superscript) virtually
abolishes the binding of PP1, whereas deletion of the C-terminal
residues 330–351 enables associated PP1 to be constitutively activeis mediated by the ForkHead-Associated (FHA) domain of NIPP1,
which speciﬁcally binds to phosphorylated threonines that are fol-
lowed by a proline [8–12]. The established FHA-ligands of NIPP1
include the pre-mRNA splicing factors SAP155 and CDC5L, the chro-
matin modiﬁer EZH2 and protein kinase MELK [8–10,12].
Additional investigations revealed that NIPP1 functions in spliceo-
some assembly [13] and transcriptional silencing by the histone
methyltransferase EZH2 [12,14,15] in a PP1-dependent manner.
NIPP1 also promotes the Cdc42-dependent migration of HeLa can-
cer cells, but the involved FHA-ligand is not known [16].
The deletion of NIPP1 in mice is embryonic lethal at E6.5–7.5,
suggesting that NIPP1 is essential for lineage speciﬁcation [17].
Here, we show that a mild (<10%) overexpression of NIPP1 in
human epithelial HeLa cancer cells resulted in the massive expres-
sion of mesenchymal genes. This effect was critically dependent on
the PP1 and substrate-binding domains of NIPP1, demonstrating a
key role for dephosphorylation of PP1-NIPP1 substrates in the dif-
ferentiation process.
2. Materials and methods
2.1. Antibodies
Immunoblots were incubated with anti-a-tubulin (clone B-5-1-
2) and anti-Flag (M2, 200472-21; Sigma–Aldrich, St. Louis, MO),
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Dakocytomation, Gostrup, Denmark), anti-CNN1 (464794) and
anti-TAGLN (ab14106; Abcam, Cambridge, UK). Anti-NIPP1 (mAb
15B8C11) was homemade [15].
2.2. Cell culture
HeLa Tet-Off (HTO) cell lines expressing Flag-tagged fusions of
NIPP1 variants in the absence of Doxycycline (Dox) were obtained
as previously described [7]. HeLa Flp-In T-Rex cells (Invitrogen)
that stably expressed EGFP or EGFP-tagged NIPP1 fusions in the
presence of Dox were generated according to the manufacturer’s
instructions. Brieﬂy, the cDNAs were cloned into the pcDNA5/
FRT/TO plasmid and co-transfected into HeLa Flp-In T-Rex host
cells (generous gift of Dr. Jonathon Pines, The Gurdon Institute,
Cambridge, UK) with the pOG44 plasmid that encoded the Flp
recombinase. Following hygromycin selection, single cell clones
were picked and expanded to obtain clonal cell lines. Proper inte-
gration was veriﬁed by lack of b-galactosidase activity. Stable cells
were cultured in DMEM-Low glucose medium (Sigma–Aldrich),
supplemented with 10% tetracycline-reduced fetal bovine serum,
100 U/ml penicillin and 100 lg/ml streptomycin (Sigma–Aldrich),
200 lg/ml Hygromycin-B (Calbiochem) and 5 lg/ml Blasticidin
(InvivoGen). Proliferation assays were performed using MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide).
HTO cells were cultured for 48 h with and without doxycycline.
MTT (0.5 mg/ml) was added for 3 h. The crystals were dissolved
in DMSO and the absorbance was measured at 595 nm.
2.3. Protein extracts and immunoblotting
HTO and HeLa Flp-In cells were harvested and lysed for 20 min
at 4 C in a buffer containing 50 mM Tris–HCl at pH 7.5, 0.3 M
NaCl, 0.3% Triton X-100, 0.1% NP-40, 0.5 mM phenylmethanesul-
fonyl ﬂuoride, 0.5 mM benzamidine, 5 lM leupeptin, 20 mM
sodium ﬂuoride and 1 lM vanadate. The lysates were clariﬁed by
centrifugation (10 min at 500g) and the supernatant was pro-
cessed for SDS–PAGE and immunoblotting. Immunoblots were
visualized using eCL reagent (Perkin Elmer, Life Sciences) in the
ImageQuant LAS4000 imaging system (GE Healthcare).
2.4. Confocal microscopy and immunocytochemistry
HTO cells were washed twice with PBS and ﬁxed for 10 min
with 4% formaldehyde. Cell permeabilization was performed by
an incubation for 5 min in PBS, supplemented with 0.5% Triton
X-100. The permeabilized cells were washed 3 times for 10 min
with PBS, pre-incubated for 20 min with PBS containing 3% bovine
serum albumin, and then incubated overnight with ACTA2 anti-
body. After three washes of 10 min each with PBS, the cells were
incubated for 1 h with Alexa Fluor 546 labeled phalloidin (Life
technologies) and mouse secondary antibody (Life Technologies)
that was labeled with Alexa ﬂuor 488. Finally, the cells were
washed 3 times for 10 min in PBS. Confocal images were obtained
with a Zeiss LSM-510(META) laser-scanning confocal microscope
(Jena, Germany), equipped with the Zeiss Axiovert 200 M
(Plan-Neoﬂuar 40/1.3 Oil DIC objective), at the Cell-Imaging-
Core of KU Leuven.
2.5. Contractility assays
96 h after doxycycline removal, the HTO cells were incubated
with 40 mM KCl and observed for 20 min with a bright ﬁeld
exposure on a motorized inverted IX-81 microscope, controlled
by Cell-M software and equipped with a temperature, humidity,and CO2-controlled incubation chamber (Olympus, Aartselaar,
Belgium). Photographs were taken every 20 s.
2.6. Microarray analysis
RNA from four independent cultures of the parental and Flag-
NIPP1-Pa expressing HTO cell line was labeled with a single ﬂuo-
rescent dye and hybridized onto Whole Human Genome Oligo
microarrays from Agilent (Santa Clara, CA, USA), as previously
described for the NIPP1-Wt and NIPP1-Pm cell lines [15].
Expression levels were analyzed using Signiﬁcance Analysis of
Microarrays (SAM) software [18]. The data from the parental cell
line were used as a baseline expression for comparison with the
Flag-NIPP1 cell lines. For the calculation of 95% conﬁdence inter-
vals on correlation coefﬁcients, the correlation coefﬁcient was sub-
jected to the Fisher’s z transformation, followed by back-
transformation of the Student’s t 95% conﬁdence interval on the
resulting z score. Data were analyzed by IPA (Ingenuity
Systems, www.ingenuity.com). The differentially regulated genes
(P < 0.01) in Flag-NIPP1-Wt and Flag-NIPP1-Pa were uploaded into
the application. The IPA analysis identiﬁed the biological functions
that were most signiﬁcant for the data set. Right-tailed Fisher’s
exact test was used to calculate a P-value determining the proba-
bility that each biological function assigned to that data set is
due to chance alone. All gene expression data are available at
GEO under accession numbers GSE19642 and GSE67558.
2.7. Quantitative RT-PCR
Total RNA was isolated using the Genelute Mammalian Total
RNA Miniprep kit (Sigma). RNA (2 lg) was reverse-transcribed
with oligo dT primer (Sigma) using the RevertAid Premium
Reverse Transcriptase and RiboLock RNase inhibitor enzymes
(Fermentas, GmBH, St Leon-Rot, Germany). About 1.2% of the
cDNA was PCR-ampliﬁed in duplicate, using SYBR Green qPCR
Mix (Invitrogen, Paisley, UK) and a Rotorgene detection system
(Corbett Research, Cambridge, UK), as described by Nuytten et al.
[14]. Quantitative reverse transcriptase PCR was performed to
check the transcript levels of ACTA2 (50-ACTGGGACGACATGGAAAA
G-30 and 50-TACATGGCTGGGACATTGAA-30), and TAGLN (50-AGA
ATGGCGTGATTCTGAGC-30 and 50-GCTCCATCTGCTTGAAGACC-30).
Data were normalized against the housekeeping gene HPRT
(50-TGACACTGGCAAAACAATGCA-30 and 50-GGTCCTTTCACCAGCAA
GCT-30).
3. Results
3.1. NIPP1 induces mesenchymal-lineage speciﬁc genes in a PP1-
dependent manner
We started our analysis using previously described HeLa Tet-Off
(HTO) cell lines that stably express Flag-NIPP1 fusions in the
absence of doxycycline [7]. The cell lines expressed a Flag-fusion
with wild type NIPP1 (NIPP1-Wt), a PP1-binding mutant (NIPP1-
Pm) or a mutant that is associated with constitutively active PP1
(NIPP1-Pa) (Fig. 1A). NIPP1-Pm was generated by mutation of resi-
dues 201 and 203 in the RVxF-type PP1 binding site, which largely
abolishes the binding of NIPP1 to PP1 [5,6]. NIPP1-Pa lacks the C-
terminal residues 330–351, comprising a PP1-inhibitory region
[6]. The Flag-tagged fusions were expressed at levels that were
2–3-fold higher than that of endogenous NIPP1 (Fig. 1B). A compar-
ative gene expression analysis using previously published data for
NIPP1-Wt and NIPP1-Pm [15], and newly analyzed whole genome
oligo-microarray proﬁling data for NIPP1-Pa revealed striking dif-
ferences between the cell lines (Fig. 1C). A paired SAM analysis
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Fig. 1. The ectopic expression of NIPP1-Wt/Pa activates mesenchymal-lineage speciﬁc genes in HeLa cells. (A) Scheme of the Flag-tagged NIPP1 fusions that were used to
generate stable HTO cell lines. (B) The parental (Co) and Flag-NIPP1 expressing HTO cells were cultured for 72 h in the absence of Dox and the levels of endogenous NIPP1
(black arrow head) and the Flag-fusions (white arrow heads) were visualized by immunoblotting. Tubulin served as a loading control. (C) 72 h after Dox removal, RNA was
isolated and a microarray analysis was performed. Venn diagrams illustrating the overlap in signiﬁcantly altered genes (P < 0.01) for the indicated comparisons. (D) Scatter
plots of the indicated log2-transformed ratios, including the data points with signiﬁcantly altered expression for the ratio indicated on the X-axis. The Pearson’s correlation
coefﬁcient (r) with conﬁdence interval is shown in each plot.
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NIPP1-Wt cells, as compared to the parental control cell line. In
contrast, 2230 (P < 0.01) and 185 genes (P < 0.01) were differen-
tially expressed in the NIPP1-Pa and NIPP1-Pm expressing cells,
respectively (Supplemental Table 1). Thus, the number of affected
genes was reduced by 90% for the PP1-binding mutant of NIPP1
and increased by 67% for the mutant that is associated with consti-
tutively active PP1. Despite these differences, there was a large
overlap between the genes that were affected in the three cell lines
(Fig. 1C). For example, 67% of the genes that showed a differential
expression in the NIPP1-Wt cells were also affected in the NIPP1-
Pa cells. Furthermore, scatter plot analysis revealed that the genes
that were signiﬁcantly affected by NIPP1-Wt were also affected by
NIPP1-Pa (r = 0.95 ± 0.0042), and vice versa (r = 0.92 ± 0.0046)
(Fig. 1D). In general, the effects of an expression of NIPP1-Pa were
more pronounced than those of NIPP1-Wt, as indicated by the dif-
ferent slope values (0.96 versus 0.80) of both plots (Fig. 1D).
An Ingenuity Pathway Analysis (IPA) of the genes that were sig-
niﬁcantly affected by the expression of NIPP1-Wt or NIPP1-Pa
showed that 739 out of 918 commonly altered genes could be clas-
siﬁed by their biological function (Fig. 2A). Interestingly, on aver-
age 79% of the genes in each class were upregulated by the
expression of NIPP1-Wt/Pa and highly enriched for the IPA cate-
gories ‘cardiovascular system development and function’ and ‘tis-
sue morphology’. The enrichment for genes of the mesenchymal
lineage was striking given that HeLa cells have an epithelial origin.
Fig. 2B illustrates the upregulation of the transcripts of some key
markers of smooth-muscle, cardiac and mesenchymal-matrix
speciﬁc genes by the expression of NIPP1-Wt or NIPP1-Pa, but
not by the expression of NIPP1-Pm. Collectively, these data showthat NIPP1 activates mesenchymal transcriptional programs in a
PP1-dependent manner.
3.2. NIPP1 induces the transdifferentiation of HeLa cells
Next, we investigated the functional consequence of the altered
transcriptome in Flag-NIPP1 expressing HTO cells. Consistent with
the microarray data, immunoblotting revealed that ACTA2 (a-
smooth muscle actin), TAGLN (smooth muscle protein 22 alpha)
and CNN1 (basic smooth muscle calponin 1) were not detectable
in the parental (Co) and NIPP1-Pm cell lines, but were highly
expressed in the NIPP1-Wt and NIPP1-Pa cell lines (Fig. 3A). For
ACTA2 and TAGLN the overexpression was more pronounced in
the NIPP1-Pa cell line, in accordance with their more elevated tran-
script levels (Fig. 2B). However, immunoblotting did not reveal a
differential expression of the cardiac-speciﬁc protein CDH13 (H-
cadherin; not illustrated), which contrasts with the huge differ-
ences in the CDH13 transcript level in the HTO cell lines
(Fig. 2B). Therefore, we have selected the smooth-muscle network
for further analysis.
At the transcript level, the smooth-muscle genes ACTA2, TAGLN
and CNN1 were among the 20 most upregulated genes in the
NIPP1-Wt and NIPP1-Pa expressing HTO cells (Fig. 2B). We also
detected an upregulation of numerous other transcripts encoding
proteins linked to smooth-muscle contraction, including the
calmodulin and actin-binding protein caldesmon (CALD1), tropo-
myosin (TPM1), and the calcium-activated potassium channel sub-
unit beta-1 (KCNMB1) (Fig. 3B and Supplemental Fig. 1). The latter
is predominantly expressed in vascular smooth-muscle cells and
was the second highest upregulated gene in NIPP1-Pa expressing
Smooth-muscle genes Cardiac genes Mesenchymal-matrix markers
A
B
Fig. 2. NIPP1 mainly induces smooth/cardiac-muscle and mesenchymal matrix genes. (A). Table showing the results of an IPA analysis of the genes that were signiﬁcantly
affected by the expression of NIPP1-Wt/Pa. (B) Bar charts of microarray data showing the relative expression levels of the indicated genes after induction of the indicated
NIPP1 fusions. The data are expressed as a fold change ± S.E.M. (n = 4), as compared to the parental cell line (Co). ⁄P < 0.01.
N. Van Dessel et al. / FEBS Letters 589 (2015) 1314–1321 1317HTO cells. In addition, transcripts for kinases involved in smooth-
muscle contraction, including myosin light-chain kinase (MYLK)
and ROCK2 kinase (ROCK2), were signiﬁcantly upregulated in the
NIPP1-Wt/Pa HTO cells. Also, several genes involved in actin
stress-ﬁber formation were upregulated following the expression
of NIPP1-Wt/Pa, including non-muscle myosin (MYH9) and regula-
tory light-chain myosin (MYL9). Consistent with this altered gene
expression pattern, phalloidin stainings showed a clear increase
in the number of stress ﬁbers in the NIPP1-Wt/Pa expressing
HTO cells, but not in NIPP1-Pm cells (Fig. 3C). Moreover, ACTA2
partially co-localized with the stress ﬁbers.
The functionality of the stress ﬁbers was determined by com-
paring the ability of the HTO cells to contract in the presence of
a depolarizing KCl concentration [19]. In this condition, we
detected retracting ﬁlopodia in 16% of the parental cells, which
increased to 40% for the NIPP1-Pa expressing cells (Fig. 3D).
Hence, the expression of NIPP1-Wt/Pa in HTO cells causes their
conversion into smooth-muscle like cells.
Since differentiation is generally associated with a reduced pro-
liferation, we also compared the proliferation potential of the HTO
cells. The expression of Flag-NIPP1-Wt reduced the proliferation
rate of the HTO cells, as measured by MTT assays (Fig. 3E).
NIPP1-Pa was an even stronger inhibitor of cell proliferation,
whereas NIPP1-Pm had no effect.
Since NIPP1 overexpression induced the expression of mes-
enchymal genes, we have also examined whether the reverse is
true too. However, the knockdown of NIPP1 in differentiated
C2C12 myoblasts cells did not affect the transcript levels of
ACTA2 and TAGLN (not shown).3.3. The induction of mesenchymal genes only requires a modest
overexpression of NIPP1
Strikingly, cell proliferation was already signiﬁcantly inhibited
by the leaky expression of the uninduced NIPP1-Wt/Pa transgenes
(Fig. 3E, +Dox). This prompted us to explore in more detail the
dependency of the transdifferentiation phenotype on the level of
the expressedNIPP1 fusions. TAGLN,ACTA2andCNN1were induced
to a similar extent in the absence or presence of Dox, despite the
hugely different expression levels of the Flag-NIPP1-Wt/Pa fusions
(Supplemental Fig. 2). Yet, these effects appeared speciﬁc as the
smooth-muscle geneswere not detectably expressed in the parental
and NIPP1-Pm expressing cell lines. These data therefore indicate
that even a small increase (8 ± 5%) in the level of NIPP1 is sufﬁcient
to induce the expression of mesenchymal genes in HeLa cells.
To further validate our data, we generated another set of stable
HeLa cell lines, using the Flp-In T-Rex system [20]. This strategy
allows the insertion of transgenes in a well-deﬁned locus, thereby
eliminating artefacts due to random integration. Also, we used a
different tag (EGFP) and a reversed Dox-dependency (induction
by Dox). Fig. 4A illustrates the expression of EGFP or EGFP-
NIPP1-Wt in a Dox-dependent manner. We again noted that the
overexpression of NIPP1-Wt, but not of EGFP, resulted in the induc-
tion of smooth-muscle genes, as detected by qRT-PCR (Fig. 4B).
Also, the maximal effect was already obtained in the absence of
Dox, when only trace amounts of EGFP-NIPP1 were expressed
due to promoter leakiness. These data conﬁrm that the expression
of smooth-muscle genes is already induced by small increments in
the level of NIPP1.
Smooth-muscle genes
A C
B
D
E
Fig. 3. NIPP1-Wt/Pa endows HeLa cells with contractile properties. (A) Immunoblotting of the indicated proteins in HTO cell lysates. The expression of the fusion proteins was
conﬁrmed with monoclonal anti-Flag and anti-NIPP1 antibodies. Tubulin served as a loading control. (B) Bar charts of microarray data of the indicated genes, after induction
of NIPP1 fusion proteins. Data are expressed as a fold change ± S.E.M. (n = 4), as compared to the control cell line (Co). ⁄P < 0.01. (C) Confocal (immuno)ﬂuorescence images of
the indicated markers in HeLa cells after the expression of the indicated NIPP1 fusions. ACTA2, a-smooth muscle actin; Phalloidin, ﬂuorescent probe for ﬁlamentous actin.
Scale bars represent 10 lm. (D) Contractility assays were performed in response to the depolarizing agent KCl. Photographs of the control and HTO Flag-NIPP1-Pa cells were
taken at 0, 10 and 20 min after the addition of 40 mM KCl. Arrows indicate a representative contracted cell. Bar diagrams show the percentage of HTO parental (n = 64) and
HTO Flag-NIPP1-Pa (n = 48) cells that contracted a ﬁlopodium after KCl stimulation. (E) MTT proliferation assays of indicated HTO cell lines before and after the induction with
Dox.
1318 N. Van Dessel et al. / FEBS Letters 589 (2015) 1314–1321
A B
Fig. 4. The expression of smooth-muscle genes in HeLa only requires a minimal overexpression of NIPP1. (A) HeLa Flp-In T-Rex cell lines with inducible and stably integrated
EGFP or EGFP-NIPP1-Wt were cultured without () and with increasing amounts of Dox from 62.5 to 1000 pg/ml. The ectopic expression of EGFP and EGFP-NIPP1-Wt was
analyzed by immunoblotting with anti-EGFP and anti-NIPP1 antibodies. Tubulin was used as a loading control. (B) The relative mRNA levels of ACTA2 and TAGLN were
measured by qRT-PCR in the same cell lines. HPRT was used for normalization and data were presented as a percentage of control ± S.E.M. (n = 3). Data were compared to the
control cell line treated with the same dose of Dox. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001 with the paired Students’s t-test.
BA
C
Fig. 5. The expression of smooth-muscle genes requires PP1 and a functional FHA domain. (A) Diagram of the EGFP-tagged NIPP1 fusions. (B) The expression of the EGFP-
fusions was analyzed by immunoblotting with anti-NIPP1 (NIPP1) and anti-EGFP antibodies. Tubulin was used as a loading control. (C) The relative mRNA levels of ACTA2 and
TAGLN were measured by qRT-PCR in the indicated cell lines. Data were normalized against HPRT and presented as a percentage of the EGFP control cell lines ± S.E.M. (n = 3).
Stars indicate a signiﬁcant difference in relative mRNA expression compared to EGFP-NIPP1-Wt. ⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001 with the paired Students’s t-test.
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1320 N. Van Dessel et al. / FEBS Letters 589 (2015) 1314–13213.4. The induction of mesenchymal genes depends on the FHA-domain
of NIPP1
Using the Flp-In T-Rex system, we have also generated cell lines
that expressed EGFP-NIPP1-Pm (Fig. 5A and B). Consistent with our
data in HTO cells, this fusion did not induce the expression of
smooth-muscle genes. In addition, we have generated cell lines
with a mutated phosphate-binding loop (alanine mutation of resi-
dues 68–71) in the substrate recruiting FHA domain of NIPP1
(NIPP1-Fm). The expression of this substrate-binding mutant did
not induce the expression of smooth-muscle genes (Fig. 5A–C).
Collectively, our data demonstrate that the NIPP1-induced transd-
ifferentiation of HeLa cells depends on associated PP1 and a func-
tional substrate-recruiting domain.
4. Discussion
We have previously demonstrated that the deletion of NIPP1 in
mice hampers gastrulation, resulting in an early embryonic lethal-
ity [17]. Conversely, here we show that NIPP1 induces a mesenchy-
mal-lineage differentiation program in a PP1 and FHA-dependent
manner. Our data are consistent with the notion that NIPP1 func-
tions through regulation of the dephosphorylation of FHA-ligands
by associated PP1. An excellent candidate to mediate this NIPP1-
induced differentiation program is the histone methyltransferase
EZH2, which has key functions in stem-cell maintenance and dif-
ferentiation, including muscle differentiation [21]. Moreover, we
have demonstrated that NIPP1 affects the phosphorylation status
of EZH2 in a PP1 and FHA-dependent manner [12,14,15], and
thereby controls its binding to a subset of target genes. However,
our preliminary data (not shown) indicate that the siRNA-induced
knockdown of EZH2 phenocopies some but not all of the observed
phenotypes of NIPP1 overexpression, indicating that additional
FHA ligands are implicated. Another good candidate to mediate dif-
ferentiation effects of NIPP1 is protein kinase MELK, which has also
been implicated in mesenchymal differentiation and cell prolifera-
tion [22,23].
The number of NIPP1 molecules is strictly controlled. Indeed,
Nipp1+/ and wild type mice express identical NIPP1 levels [17].
Also, there is a huge discrepancy between transcript and protein
levels of ectopically expressed NIPP1, which is explained by a
translation control mechanism [24]. In the present study, we
report that the NIPP1-induced differentiation phenotype only
requires a slight (<10%) overexpression of NIPP1, explaining why
the NIPP1 levels need to be so tightly controlled. We speculate that
the large effects of this very moderate overexpression of NIPP1 are
due to the low abundance of key FHA-ligands. For example, 10%
overexpression of NIPP1 corresponds to 12000 extra NIPP1 mole-
cules, which is still 25 times more than the number of EZH2 mole-
cules in HeLa cells [25].
In conclusion, we have shown here that NIPP1 induces the
expression of genes of the mesenchymal lineage in HeLa cells in
a PP1 and FHA-dependent manner. This leads to the enticing
hypothesis that key dephosphorylation event(s) underly the mes-
enchymal differentiation program.
Conﬂict of interest
The authors declare no conﬂict of interests.
Acknowledgements
This work was supported by the Belgian Foundation Against
Cancer and FWO – Flanders Grant G048212N. We thank Fabienne
Withof and Annemie Hoogmartens for expert technical assistance,
and Dr. Maria Andries for performing CDH13 immunoblots.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2015.04.
017.
References
[1] Bollen, M., Peti, W., Ragusa, M.J. and Beullens, M. (2010) The extended PP1
toolkit: designed to create speciﬁcity. Trends Biochem. Sci. 35, 450–458.
[2] Heroes, E., Lesage, B., Görnemann, J., Beullens, M., Van Meervelt, L. and Bollen,
M. (2013) The PP1 binding code: a molecular-lego strategy that governs
speciﬁcity. FEBS J. 2, 584–595.
[3] Jagiello, I., Beullens, M., Stalmans, W. and Bollen, M. (1995) Subunit structure
and regulation of protein phosphatase-1 in rat liver nuclei. J. Biol. Chem.,
17257–17263.
[4] O’Connell, N., Nichols, S.R., Heroes, E., Beullens, M., Bollen, M., Peti, W. and
Page, R.C.-P. (2012) The molecular basis for substrate speciﬁcity of the nuclear
NIPP1:PP1 holoenzyme. Structure 20, 1746–1756.
[5] Hendrickx, A., Beullens, M., Ceulemans, H., Den Abt, T., Van Eynde, A.,
Nicolaescu, E., Lesage, B. and Bollen, M. (2009) Docking motif-guided mapping
of the interactome of protein phosphatase-1. Chem. Biol. 16, 365–371.
[6] Beullens, M., Vulsteke, V., Van Eynde, A., Jagiello, I., Stalmans, W. and Bollen,
M.C.-P. (2000) The C-terminus of NIPP1 (nuclear inhibitor of protein
phosphatase-1) contains a novel binding site for protein phosphatase-1 that
is controlled by tyrosine phosphorylation and RNA binding. Biochem. J. 352 (Pt
3), 651–658.
[7] Tanuma, N., Kim, S.-E., Beullens, M., Tsubaki, Y., Mitsuhashi, S., Nomura, M.,
Kawamura, T., Isono, K., Koseki, H., Sato, M., Bollen, M., Kikuchi, K. and Shima,
H. (2008) Nuclear inhibitor of protein phosphatase-1 (NIPP1) directs protein
phosphatase-1 (PP1) to dephosphorylate the U2 small nuclear
ribonucleoprotein particle (snRNP) component, spliceosome-associated
protein 155 (Sap155). J. Biol. Chem. 283, 35805–35814.
[8] Boudrez, A., Beullens, M., Groenen, P., Van Eynde, A., Vulsteke, V., Jagiello, I.,
Murray, M., Krainer, A.R., Stalmans, W. and Bollen, M. (2000) NIPP1-mediated
interaction of protein phosphatase-1 with CDC5L, a regulator of pre-mRNA
splicing and mitotic entry. J. Biol. Chem. 275, 25411–25417.
[9] Boudrez, A., Beullens, M., Waelkens, E., Stalmans, W. and Bollen, M. (2002)
Phosphorylation-dependent interaction between the splicing factors SAP155
and NIPP1. J. Biol. Chem. 277, 31834–31841.
[10] Vulsteke, V., Beullens, M., Boudrez, A., Keppens, S., Van Eynde, A., Rider, M.H.,
Stalmans, W. and Bollen, M. (2004) Inhibition of spliceosome assembly by the
cell cycle-regulated protein kinase MELK and involvement of splicing factor
NIPP1. J. Biol. Chem. 279, 8642–8647.
[11] Kumeta, H., Ogura, K., Adachi, S., Fujioka, Y., Tanuma, N., Tanuma, K., Kikuchi,
K. and Inagaki, F. (2008) The NMR structure of the NIPP1 FHA domain. J.
Biomol. NMR 40, 219–224.
[12] Minnebo, N., Görnemann, J., O’Connell, N., Van Dessel, N., Derua, R., Vermunt,
M.W., Page, R., Beullens, M., Peti, W., Van Eynde, A. and Bollen, M. (2013)
NIPP1 maintains EZH2 phosphorylation and promoter occupancy at
proliferation-related target genes. Nucleic Acids Res. 41, 842–854.
[13] Beullens, M. and Bollen, M. (2002) The protein phosphatase-1 regulator NIPP1
is also a splicing factor involved in a late step of spliceosome assembly. J. Biol.
Chem. 277, 19855–19860.
[14] Nuytten, M., Beke, L., Van Eynde, A., Ceulemans, H., Beullens, M., Van
Hummelen, P., Fuks, F. and Bollen, M. (2008) The transcriptional repressor
NIPP1 is an essential player in EZH2-mediated gene silencing. Oncogene 27,
1449–1460.
[15] Van Dessel, N., Beke, L., Görnemann, J., Minnebo, N., Beullens, M., Tanuma, N.,
Shima, H., Van Eynde, A. and Bollen, M. (2010) The phosphatase interactor
NIPP1 regulates the occupancy of the histone methyltransferase EZH2 at
Polycomb targets. Nucleic Acids Res. 38, 7500–7512.
[16] Martin-Granados, C., Prescott, A.R., Van Dessel, N., Van Eynde, A., Arocena, M.,
Klaska, I.P., Görnemann, J., Beullens, M., Bollen, M., Forrester, J.V. and McCaig,
C.D.C.-P. (2012) A role for PP1/NIPP1 in steering migration of human cancer
cells. PLoS One 7, e40769.
[17] Van Eynde, A., Nuytten, M., Dewerchin, M., Schoonjans, L., Keppens, S.,
Beullens, M., Moons, L., Carmeliet, P., Stalmans, W. and Bollen, M. (2004) The
nuclear scaffold protein NIPP1 is essential for early embryonic development
and cell proliferation. Mol. Cell. Biol. 24, 5863–5874.
[18] Tusher, V.G., Tibshirani, R. and Chu, G. (2001) Signiﬁcance analysis of
microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci.
U.S.A. 98, 5116–5121.
[19] Ratz, P.H., Berg, K.M., Urban, N.H. and Miner, A.S. (2005) Regulation of smooth
muscle calcium sensitivity: KCl as a calcium-sensitizing stimulus. Am. J.
Physiol. Cell Physiol. 288, C769–C783.
[20] Ward, R.J., Alvarez-Curto, E. and Milligan, G. (2011) Using the Flp-In™ T-Rex™
system to regulate GPCR expression. Methods Mol. Biol. 746, 21–37.
[21] Kondo, Y. (2014) Targeting histone methyltransferase EZH2 as cancer
treatment. J. Biochem. 156, 249–257.
[22] Niesler, C.U., Myburgh, K.H. and Moore, F. (2007) The changing
AMPK expression proﬁle in differentiating mouse skeletal muscle myoblast
cells helps confer increasing resistance to apoptosis. Exp. Physiol. 92,
207–217.
N. Van Dessel et al. / FEBS Letters 589 (2015) 1314–1321 1321[23] Ganguly, R., Hong, C.S., Smith, L.G.F., Kornblum, H.I. and Nakano, I. (2014)
Maternal embryonic leucine zipper kinase: key kinase for stem cell phenotype
in glioma and other cancers. Mol. Cancer Ther. 13, 1393–1398.
[24] Wera, S., Van Eynde, A., Stalmans, W. and Bollen, M. (1997) Inhibition of
translation by mRNA encoding NIPP-1, a nuclear inhibitor of protein
phosphatase-1. Eur. J. Biochem. 247, 411–415.[25] Nagaraj, N., Wisniewski, J.R., Geiger, T., Cox, J., Kircher, M., Kelso, J., Pääbo, S.
and Mann, M.C.-P. (2011) Deep proteome and transcriptome mapping of a
human cancer cell line. Mol. Syst. Biol. 7, 548.
